CVI42
CIRCLE CARDIOVASCULAR IMAGING INC • Radiology • 08/22/2014
Device Purpose
cvi42 is a specialized software add-on that employs advanced image processing and visualization techniques for the detailed analysis of vascular structures from CT and MR medical imagery. Its primary purpose is to furnish qualified medical professionals with precise tools for evaluating, documenting, and monitoring physician-identified vascular lesions, thereby augmenting diagnostic support in the field of cardiovascular imaging.
Summary
cvi42 is a specialized software add-on designed for the analysis of vascular structures within CT and MR images. It equips clinicians with a range of digital image processing and visualization tools, such as multiplanar reconstruction (MPR), various forms of maximum intensity projection (MIP), volume rendering technique (VRT), and curved planar reformation. Essential processing capabilities for vascular analysis include bone removal, with support for both single and dual-energy CT data, and table removal. Furthermore, its evaluation tools are engineered to facilitate vessel centerline calculation, lumen assessment, and stenosis quantification, all aimed at supporting physicians in the confirmation or exclusion of physician-identified vascular lesions. This software add-on also plays a crucial role in the comprehensive evaluation, documentation, and subsequent follow-up of any identified vascular lesions. It achieves this through dedicated reporting tools that meticulously capture lesion location, detailed characteristics, and pertinent key images. cvi42 is intended for use by qualified medical professionals who are experienced in the examination and interpretation of cardiovascular CT or MR images. It functions as an integral part of a comprehensive diagnostic decision-making process and can be deployed either as a standalone product or within a networked environment, focusing on delivering detailed analytical capabilities for vascular images to enhance patient management and the monitoring of vascular conditions.
AI Regulatory Concerns
Powered by
Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.
Keywords
Device Metadata
Relevant Clinical Questions
- Q1. How does the dual-energy CT bone removal algorithm in cvi42 specifically improve vessel visualization compared to single-energy techniques, particularly in complex vascular anatomies or in the presence of calcified plaque?; What is the validated accuracy and reproducibility of the lumen diameter and stenosis percentage calculations provided by cvi42 when compared against invasive reference standards like quantitative angiography or intravascular ultrasound?; Does cvi42 offer tools for longitudinal analysis, allowing for the co-registration and quantitative comparison of vascular changes across multiple imaging studies obtained at different time points for the same patient?; What are the specific output formats for the reporting tools (e.g., lesion location, characteristics), and do they allow for structured data export that can be integrated into Electronic Medical Record (EMR) or Radiology Information Systems (RIS)?; How does cvi42 handle variations in image quality or common artifacts (e.g., motion artifacts in MR, beam hardening in CT) that might affect the accuracy of automated measurements like vessel centerline extraction or lumen boundary detection?
Risk Classification
ESL AnalysisFDA Class II via 510(k) pathway; IEC 62304 Class B (software safety classification); Authorized before §524B enforcement
Learn how Parasoft automates IEC 62304 compliance testing →Cybersecurity Evidence
Powered by SBOMator™Based on AI-generated device summaries, not the full FDA submission. Items not detected here may still be present in the complete submission package.
Supply Chain BOM Evidence
Based on the CycloneDX / OWASP ECMA-424 xBOM ecosystem. Detection is from the AI-generated summary.
Analysis:
• Analysis is based on the AI-generated device summary, not the full FDA submission package. Click "Analyze Full FDA PDF" below to scan the actual submission document.
• Evidence of ML-BOM, SaaSBOM, OBOM detected in AI-generated device summary.
• This device was authorized before §524B took effect. Cybersecurity evidence requirements were less prescriptive at the time.
• Not detected in AI-generated device summary: SBOM, HBOM, CBOM, VDR/VEX. These may be present in the full FDA submission.
Preparing a similar submission?
ESL takes complete ownership of your software evidence work - SBOM & CVE remediation with SBOMator™, static analysis & unit testing with Parasoft, traceability, and full IEC 62304 lifecycle support.
Assess Your Readiness →Or contact ESL directly